S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

PTN Palatin Technologies Inc New

1.08

0.01 (0.93%)

Nov 27 2024 - Closed

Delayed by 15 minutes

Form 424B3 - Prospectus [Rule 424(b)(3)]

null

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies Inc New News

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Monday 25 November 2024 (3 days ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Thursday 14 November 2024 (2 weeks ago) • PR Newswire (US)

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Friday 8 November 2024 (3 weeks ago) • PR Newswire (US)

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Monday 4 November 2024 (3 weeks ago) • PR Newswire (US)

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Thursday 31 October 2024 (4 weeks ago) • PR Newswire (US)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Wednesday 30 October 2024 (4 weeks ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Tuesday 29 October 2024 (4 weeks ago) • Edgar (US Regulatory)

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Thursday 24 October 2024 (1 month ago) • PR Newswire (US)

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Wednesday 23 October 2024 (1 month ago) • PR Newswire (US)

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Tuesday 22 October 2024 (1 month ago) • Edgar (US Regulatory)

More Palatin Technologies Inc New News Articles

Santo Mining (CE)

ERHC Energy (CE)

Bioelectronics (PK)

Asia Broadband (PK)

Kraig Biocraft Laborator... (QB)

Global Developments (PK)

North Bay Resources (PK)

Digital Brand Media and ... (PK)

Anavex Life Sciences

Northwest Biotherapeutics (QB)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions